GPR4 Blocking PeptideCatalogue number: X1646B
|Product Type||Blocking Peptide|
|Application||Antibody function blocking|
Sphingosylphosphorylcholine (SPC) and lysophosphatidylcholine (LPC) are bioactive lipid molecules involved in numerous biologicals processes. GPR4 shares sequence homology with OGR1 (51%), the highest of all GPCRÕs. GPR4 has been identified as another high affinity receptor for SPC and low affinity receptor for LPC. SPC and LPC stimulate kinase activation and DNA synthesis stimulated, both of which are pertussis toxin-sensitive, suggesting Gi-heterotrimeric G protein involvement. The GPR4 subfamily of GPCRÕs consists of four receptors that share significant sequence homology; OGR1, TDAG8 and G2A. G2A has been shown to be a potent transforming oncogene. GPR4 also malignantly transforms NIH3T3 cells and TDAG8 malignantly transforms the normal mammary epithelial cell line NMuMG. Overexpression of GPR4 or TDGA8 in HEK293 cells leads to transcriptional activation independent of exogenously added ligand. TDAG8 and GPR4 are also overexpressed in a range of human cancer tissues suggestive of a driving role in maintaining tumor formation.
Product Form: Unconjugated
Formulation: Provided as solution in phosphate buffered saline with 0.08% sodium azide
Concentration: See vial for concentration
For use with GPR4 polyclonal antibody (Cat. No. X1638P).
Functional Analysis: Western Blotting
Product should be stored at -20ºC. Aliquot to avoid freeze/thaw cycles
Product Stability: Products are stable for one year from purchase when stored properly
Shipping Conditions: Ship at ambient temperature, freeze upon arrival
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals.
Safety Datasheet(s) for this product:
GPR4 Blocking Peptide